{"url_path":"/sec/avir/8-k/2026-06-22/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1593899/0001193125-26-277639-index.html","accession_number":"0001193125-26-277639","cik":"0001593899","ticker":"AVIR","issuer_name":"Atea Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1593899/0001193125-26-277639-index.html","primary_entity_key":"0001593899","primary_entity_name":"Atea Pharmaceuticals, Inc."},"word_count":319,"has_tables":true,"body_markdown":"Item 5.07.\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn June 18, 2026, Atea Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 59,742,819 shares of the Company’s common stock were present in person or represented by proxy at the Annual Meeting, representing approximately 74.65% of the Company’s common stock outstanding as of the April 24, 2026 record date.\n\nBelow are the final voting results certified by Broadridge Financial Solutions, Inc., the inspector of election, for the proposals considered and voted upon at the Annual Meeting. Each of these proposals were described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 27, 2026.\n\nProposal 1 — Election of three Class III Directors to serve until the 2029 annual meeting of stockholders, and until their respective successors have been duly elected and qualified.\n\n \n\n \n \n\nFOR\n\n \n\nWITHHOLD\n\n \n\nBROKER\n\nNON-VOTE\n\nJerome Adams, MD, MPH\n\n \n28,798,012\n \n22,275,665\n \n8,669,142\n\nHoward Berman, PhD\n\n \n44,466,627\n \n6,607,050\n \n8,669,142\n\nBarbara Duncan\n\n \n43,697,098\n \n7,376,579\n \n8,669,142\n\nProposal 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.\n\n \n\nFOR\n\n \n\nAGAINST\n\n \n\nABSTAIN\n\n \n\nBROKER\n\nNON-VOTE\n\n58,894,207\n\n \n783,081\n \n65,531\n \n0\n\nProposal 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.\n\n \n\nFOR\n\n \n\nAGAINST\n\n \n\nABSTAIN\n\n \n\nBROKER\n\nNON-VOTE\n\n47,452,759\n\n \n2,977,290\n \n643,628\n \n8,669,142\n\nBased upon the foregoing votes, Dr. Jerome Adams, Dr. Howard Berman and Barbara Duncan were elected as Class III directors and Proposals 2 and 3 were approved.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nATEA PHARMACEUTICALS, INC.\n\nDate: June 22, 2026\n \n\n \nBy:\n \n\n/s/ Andrea Corcoran\n\n \n\n \n\n \nAndrea Corcoran\n\n \n\n \n\n \nChief Financial Officer and Executive Vice President, Legal and Secretary"}